+86 21 2215 7611 228 Weihai road • 16F Merchant Plaza • SHANGHAI 200041 • CHINA 

Chinese Pharma & Biotech Press Review - N° 224



Dear customers,
We extend our sincerest wishes for a merry Christmas and a successful year 2012.
We will be happy to meet you again in January, with new reports and news on China.
Please, do not hesitate to contact us if you need any information: contact@universalmedica.cn
Merry Christmas!


  • China will continue its fight against counterfeit drugs
  • Boehringer Ingelheim Sets $91 Million Shanghai Expansion
  • Pfizer and GSK boost pneumonia vaccine price cuts for developing world
  • India, China boosting API: Companies & Markets

Healthcare News

Dehaier Medical Enters European Homecare Medical Product Market
(Market Watch, 2011-12-16)
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, announced that it has signed on three Romanian companies to distribute Dehaier’s DHR-5L oxygen concentrators in Romania. This marks Dehaier’s first entry into the European homecare medical product market.

Chindex International, Inc. Announces Opening of Latest Premium Hospital in Tianjin
(Reuters, 2011-12-20)
Chindex International, Inc, an American health care company providing health care services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, announced the official opening of its Tianjin United Family Hospital, one of the latest development projects of the United Family Healthcare network. The company held an opening and ribbon-cutting ceremony for Tianjin United Family Hospital in December, which was attended by distinguished guests including Mr. Gary Locke, the U.S. Ambassador to People’s Republic of China.

WHO warns Chinese public of misleading tobacco industry research
(Topix, 2011-12-19)
Research indicating that some cigarettes are less harmful is tobacco industry hype meant to mislead the public, a WHO official warned as a heated debate rages in China over the credibility of tobacco science. “Low-tar cigarettes, for example, don’t reduce the harm at all,” said Sarah England, a technical officer on tobacco control with the WHO Representative Office in China. She said tar, nicotine and other smoke emission yields derived from smoking-machine testing do not provide valid estimates of human exposure and there is no conclusive epidemiological or scientific evidence that cigarettes with lower machine-generated smoke yields are less harmful.

China will continue its fight against counterfeit drugs
(中国网, 2011-12-20)
China will continue next year its strong political fight against counterfeit drugs, announced the SFDA. Shao Mingli, director of the SFDA spoke at a national conference on the supervision and management of food and pharmaceutical products. China launched a special campaign of two years on the safety of pharmaceuticals (between July 2009 and July 2011), during which the authorities have investigated more than 42,000 cases and closed 1,093 illegal websites. The SFDA will control the information and transactions online related to pharmaceuticals and establish a monitoring network covering all the prefectures of the country, added Shao.

Pharmaceutical Industry

Sihuan Pharma Building $110 Million Facility in Beijing
(Scoop.pharma-digital, 2011-12-15)
Sihuan Pharmaceutical broke ground on a new 700 million RMB ($110 million) campus that will house production, R&D and offices. The 175 acre site is located in the Zhangwan Development Area, Tongzhou District, Beijing. Founded in 2001, Sihuan claims to have the largest market share of cardio-cerebral drugs in China. After completing its IPO last year, the company has been very busy, completing several M&A deals and investing in new facilities.

Boehringer Ingelheim Sets $91 Million Shanghai Expansion
(Asian Scientist, 2011-12-16)
Boehringer Ingelheim announced a $91 million expansion of its Shanghai manufacturing facility, which is located in Zhangjiang High-Tech Park. The German company positioned the investment as a “for China” strategy. The latest boost to BI’s China facilities follows a $149 million investment two years ago at the same site, aimed at increasing the company’s offerings in vaccines and animal health.

DSM Sinochem JV Building Second China Anti-Infective Facility
(Bioportfolio, 2011-12-20)
DSM Sinochem Pharma announced plans to build a manufacturing facility, located in Shandong province, to produce semi-synthetic cephalosporins (SSC). The facility will use DSM Sinochem’s efficient biotech manufacturing process. The JV was formed earlier this year when Sinochem Pharma paid $291 million for a 50% stake in Royal DSM‘s global anti-infectives unit.

Pfizer and GSK boost pneumonia vaccine price cuts for developing world

(Fiercepharma, 2011-12-20)
Pfizer and GlaxoSmithKline said they are selling an additional 360 million doses of their pneumonia vaccine to a global health organization at a discounted $3.50 a dose. The Global Alliance for Vaccines and Immunization (GAVI) is buying the doses, split evenly between Pfizer’s Prevenar GlaxoSmithKline’s Synflorix. Both corporations will supply the vaccines through 2023. The GAVI, raised $4.3 billion in pledges from donors in June to help fund its effort to immunize children against pneumococcal disease, which kills over 500,000 children annually, mostly in the developing world, and causes pneumonia, meningitis and sepsis. GAVI hopes to prevent 7 million deaths by 2030.

Hua Medicine In-licenses Diabetes Drug Candidate from Roche
(ChinaBio Today, 2011-12-21)
Hua Medicine has in-licensed global rights to Roche’s glucokinase activator program (GKA), a potential treatment for diabetes. GKA is a novel, small molecule activator of the glucokinase enzyme, which helps to regulate carbohydrate metabolism. The product, Hua’s first in-licensing, is ready to start clinical trials. In return for exclusive global development, manufacturing and marketing rights, Hua has agreed to pay an upfront payment, milestones and royalties.

Hengrui Gains FDA Approval for Cancer Drug
(Chinese Life Science Professionals Association, 2011-12-21)
Jiangsu Hengrui Medicine has been granted FDA approval for Irinotecan, an anti-cancer drug that is usually prescribed as part of a drug cocktail for colon cancer. According to Hengrui, the approval is the first given to a China company for an injected drug. The company said it plans to use the experience of its first FDA approval to accelerate plans for US and European acceptance of other drugs in its portfolio.

Biostar Pharmaceuticals Signs 12-Month Distribution Agreement With Huikang Pharmaceuticals
(Medindia.net, 2011-12-20)
Biostar Pharmaceuticals, Inc, a developer, manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, announced that its newly acquired subsidiary, Shaanxi Weinan, signed a 12-month distribution agreement with Shaanxi Huikang Pharmaceuticals Co. effective January 1, 2012. Huikang Pharmaceuticals is distributor of pharmaceutical products in 11 provinces in Northwest and North China and has annual sales over RMB 300 million. Huikang Pharmaceuticals has a network of over 300 drugstores and hospitals, where, for the most part, Biostar products are not currently sold.


China Sky One Partners Up to Form New Stem Cell Company
(Devicespace, 2011-12-17)
China Sky One Medical, together with three partners, will invest $36.3 million to create a stem cell company, which will be called Harbin Tian Xin Biological Engineering. Besides providing umbilical cord cell banking, the new company will perform the clinical applications of bone marrow stem cells, intercord mesenchymal stem cells and other human stem cells.

Mindray Medical to Acquire a Controlling Stake in Hunan Changsha TDR Biotech
(PR Newswire, 2011-12-20)
Mindray Medical International Limited, a developer, manufacturer and marketer of medical devices worldwide, announced an agreement to acquire a controlling stake of Hunan Changsha Tiandiren Biotech Co., Ltd. TDR is a domestic manufacturer of microbiology analysis solutions that specialize in microbial identification and antibiotic susceptibility testing (ID/AST) and the blood culture system. Last year, the market for ID/AST and blood culture system was estimated at approximately $139 million in China. It is expected to grow 15-20% annually. Internationally, the market was estimated at $2.25 billion in 2010 and is expected to grow 5% annually.

Scientific News

Chinese doctors find way to detect liver cancer earlier
(新华网, 2011-12-19)
A simple test using just one milliliter of a patient’s blood can tell whether the patient has liver cancer — even if the tumor is less than two centimeters in diameter, new medical research in Shanghai shows. Doctors at the Zhongshan Hospital, a major medical institution affiliated with Fudan University, have found that seven microRNAs, or ribonucleic acid molecules, are strongly related to liver problems. This discovery can raise the accuracy of tests for early-stage liver cancer to almost 90 percent. Each test will cost a patient only about 100 yuan (15.9 U.S. dollars), said Dr. Fan Jia, vice president of the hospital and one of the country’s leading liver surgeons. China sees half of the world’s new liver cancer cases each year. More than 60 percent of Chinese liver cancer patients are diagnosed too late to be cured, according to the medical paper written by Fan’s team.

Asia/Pacific news

India, China boosting API: Companies & Markets
(BioSpectrum, 2011-12-16)
According to London based analysis company, Companies & Markets, the Development in the High Potency Active Pharmaceutical Ingredient (HPAPI) and Biogeneric drugs is boosting the growth of the Active Pharmaceutical Ingredient (API) market. There has been a paradigm shift in the use of innovative drugs to that of low-cost API drugs after the economic recession, thereby causing a positive impact on the overall growth of the API market. The Active Pharmaceutical Ingredient (API) forms the most vital part of every formulated end product, and is an important part of the whole pharmaceutical industry. The overall API market was valued at $101.08 billion in 2010, and is expected to grow at a CAGR of 7.9 percent from 2011 to 2016. There has been an increase in influence of API players from emerging economies such as India and China after the economic recession. The recession restricted the growth of Innovative sector in developed economies such as the U.S and Europe, as the Innovative sector requires huge investments. This has helped fuel the growth of Generics market in Asian countries such as India and China.